HighTower Advisors’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History
Bought
Maintained
Sold
Other funds holding XPH
MCM
FCBT
HighTower Advisors's XPH Position: Q1 2023 in Review
HighTower Advisors sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q1 2023, closing a stake of 35,641 shares — an estimated $1.46M sold.
HighTower Advisors first reported a position in XPH in Q2 2013 and held it in 23 quarters. The position peaked at $15.9M in Q3 2018. 61 funds tracked by Wall St. Rank hold XPH as of Q1 2023.
- HighTower Advisors reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q1 2023 after selling out during the quarter.
- HighTower Advisors sold 35,641 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2023, an estimated $1.46M.
- HighTower Advisors first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q2 2013 and held it in 23 quarters.
- HighTower Advisors's State Street SPDR S&P Pharmaceuticals ETF position peaked at $15.9M in Q3 2018.
- 61 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2023.
Based on HighTower Advisors's 13F filing for Q1 2023, filed 12 May 2023.